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ABSTRACT. The chemical stability and compatibility of
imipenem-cilastatin sodium (Primaxin) in two different total
parenteral nutrient (TPN) solutions was determined. TPN
solutions consisted of 4.25% and 5% amino acids with 25% and
35% dextrose, respectively.
Imipenem-cilastatin sodium was constituted with 10 ml of
sterile water and admixed with 90 ml of TPN solution for a
final concentration of 5 mg/ml of each drug. The final solutions
were assayed at times 0 (immediately after admixture), 15 min,
30 min, 1, 4, 8, and 24 hr by a stability-indicating high-
performance liquid chromatographic assay. Concurrently, test
TPN solutions were monitored for pH changes, color changes,
and precipitate formation. The potential effect of imipenem-
cilastatin sodium on the stability of amino acids and other
TPN additives was not evaluated.
Imipenem and cilastatin sodium was stable (&ge;90% re-
covered) in each TPN solution at 15 min. A significant (&ge;10%)
and steady decrease of imipenem recovery occurred at subse-
quent sampling times. Cilastatin appeared more stable than
imipenem in both TPN solutions. A physical color change from
colorless to dark orange appeared in each TPN solution over
the 24-hr study period.
Imipenem-cilastatin sodium is stable for 15 min in the TPN
solutions studied; however, until the stability of the amino
acids can be determined, the antibiotic should be administered
through a separate line or Y-site while the TPN infusion is
interrupted. (Journal of Parenteral and Enteral Nutrition
14:306-309, 1990)
Imipenem-cilastatin sodium (Primaxin) is a broad
spectrum intravenous antimicrobial product. Imipenem
is a beta-lactam antibiotic of a N-formimidoyl derivative
of thienamycin. Cilastatin sodium is a competitive inhib-
itor of a renal hydrolysis enzyme, dehydropeptidase 1.1
Cilastatin sodium, having no intrinsic antimicrobial ac-
tivity, retards the renal metabolism of imipenem.’ Imi-
penem is effective against aerobic and anaerobic Gram-
positive, Gram-negative, and beta-lactamase producing
organisms.3-6
Imipenem-cilastatin sodium, being a broad spectrum
antibiotic, is commonly used in the multiinfected septic
patient. The septic patient is occasionally a candidate
for total parenteral nutrient (TPN) solution due to the
acute stress of sepsis. Complications of sepsis include
gastrointestinal ileus, increased caloric requirements and
decreased consciousness which result in inadequate oral
nutritional intake. Therefore, TPN solution administra-
tion may be required for nutritional support. TPN solu-
tion administration has been shown to be effective for
nutritional support in inpatient and outpatient set-
tings.7-’
In the critical care patient it would be useful to infuse
imipenem-cilastatin sodium into TPN solution at a Y-
site for various reasons:
1. These patients may have limited access sites for drug
administration especially when other intravenous
fluids are being administered concomitantly.
2. Y-site administration would reduce the number of
direct intravenous lines into the patient, resulting in
decreased line and site maintenance by nursing staff.
Since imipenem-cilastatin sodium is a new antimicro-
bial agent, the stability and compatibility have not been
determined in TPN solution. Merck, Sharp and Dohme,
the manufacturer of Primaxin, states that imipenem-
cilastatin remains potent for 4 hr at room temperature
in various intravenous solutions.l° Recently, Bigley et
al&dquo; examined the stability and compatibility of imipe-
nem-cilastatin sodium (Primaxin) in seventeen intrave-
nous solutions.11 Results indicate that Primaxin is most
stable in 0.9% sodium chloride and sterile water for
injection. Stability and compatibility of imipenem-cilas-
tatin sodium with TPN formulations have not been
established. Therefore, the objective of this study was to
determine the chemical stability and compatibility of
imipenem-cilastatin sodium in two different TPN solu-




Two aseptically prepared TPN solutions were used to
evaluate imipenem-cilastatin sodium stability and com-
patibility (Table I). All procedures were carried out under
continuous fluorescent room lighting at room tempera-
ture (25°C).
Primaxin 500 mg (Merck, Sharp and Dohme, West
Point, PA, Lot 0422N) (500 mg of imipenem anhydrous/
500 mg cilastatin) was aseptically constituted with 10 ml
of sterile water and then admixed with 90 ml of TPN
solution in 150 ml evacuated infusion bottles, resulting
in a 5-mg/ml mixture of imipenem and cilastatin. The
procedure was repeated in duplicate for TPN solutions 1
and 2.
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Each test TPN mixture was aseptically sampled at
time 0 (immediately after admixture), 15 min, 30 min. 1.
4, 8, and 24 hr. Each sample was assayed in duplicate
using HPLC.
Assay Procedure
Imipenem and cilastatin concentrations were meas-
ured by HPLC in a manner similar to that described by
Bigley et al.&dquo; Chemical analysis by HPLC was performed
because it is sensitive and specific for molecular stability.
HPLC determination is superior to visual and microbi-
ological studies since there is a lack of correlation be-
tween these techniques and chemical stability.&dquo; The
stability of amino acids or other TPN additives following
addition of the imipenem-cilastatin sodium was not eval-
uated.
Samples were diluted 1:100 with the aqueous mobile
phase (0.004M 3-[N-morpholino]propanesulfonic acid
(MOPS) buffer with sodium hexane sulfate 2 g/liter plus
4 ml of acetonitrile and 5 ml of methanol added to each
liter). The mobile phase was adjusted to pH 7.00 with
sodium hydroxide. Thirty microliters from each diluted
TABLE I
Composition of TPN solutions
* Aminosyn, Abbott Laboratories, North Chicago, IL, lot 02-503-
DM-03.
sample was injected through a Rheodyne injector 125
valve (Rheodyne injector 125 valve. Rheodyne Inc. Co-
tati, CA) (100-)uL loop) onto a Hewlett-Packard RP-8
(20 cm X 0.46 cm internal diameter) column He~~-lett-
Packard, Abondale, Pr1). A Waters model 6000A solvent
delivery system (W’aters Associates. Milford, PA) and a
Lamda Max 481 UV detector (Lamda Max 481 LJV
detector, Waters Associates) were used. Peak areas were
measured automatically by a Hewlett-Packard model
3390A integrator. HPLC assay specifications were as
follows: absorbance wavelength 250 nm, AUFS 0.1, re-
sponse time 0.1 sec, attenuation 4, chart speed 0.3 cm/
min, and flow rate 1.8 ml/min. The retention time was
5.5 and 8.8 min for imipenem and cilastatin. respectively.
All solvents and water were HPLC grade.
Stability-Indicating Procedures
The HPLC assay used to determine imipenem and
cilastatin concentrations was stability indicating.1.1 A
standard of 1.0 mg/ml (drugs/water) was prepared for
imipenem-cilastatin sodium. This standard was divided
into three portions and stressed in one of three ways: the
pH of the standard was adjusted to 1.8 with phosphoric
acid, the standard solution was evaporated on a hot plate
and allowed to dry at excessive heat before reconstitution
to the exact initial volume with water, or the standard
was heated on a boiling water bath for fifteen minutes.
A standard (100 ug/ml) was prepared from each of the
three stressed standards and analyzed by HPLC. Result-
ing chromatographs were compared with those from
freshly prepared standards. The assay proved to be sta-
bility indicating; no drug decomposition product inter-
fered with the response of the intact drug under the
stressed conditions described above (Fig. 1).
Assay Validation
A standard solution ( mg/ml) of Primaxin in mobile
phase was prepared on three separate days. A standard
FIG. 1. Chromatographs of TPN solution 1 (1:100) in mobile phase L4. Imipenem (50 JIg/mIl and cilastatin (50 Esg/ml! in TPN -,olution 1 at
time zero (B); Imipenem (43 ~g/ml) and cilastatin (43 Jlg/ml> after 15 min in a boiling water bath IC). at pH 1.8 (D), and after being heat dried
and reconstituted (E). In chromatographs B, C, D, and L~’, peaks for imipenem and cilastatin are marked 1 and c, respectively. All other peaks in
chromatographs C, D, and E are degradation products.
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curve was performed in duplicate on each day over a
concentration range of 0 to 86.4 ~g/ml of imipenem and
cilastatin. The slope of each curve was calculated by
linear least-squares regression analysis. The six standard
curves were reproducible (imipenem slope = 7.30 ± 0.20;
cilastatin slope = 7.28 ± 0.48) and linear (imipenem r~ 2
= 0.9991 ± 0.0004; cilastatin r~ = 0.9991 ± 0.0003). Based
on the slope of each standard curve, a calculated concen-
tration was computed for each peak area. The percent
deviation for each calculated concentration was com-
puted as follows:
The average percent deviation of the calculated concen-
trations for imipenem and cilastatin standard curves was
2.15% ± 2.93% and 2.15% ± 2.83%, respectively.
pH Measurement and Solution Color
Each test TPN solution was analyzed for pH and
physical changes at each sampling time. An electrode
Corning 135 pH meter was used. At each sampling time
an additional 3-ml aliquot was removed and analyzed for
pH changes. Concomitantly, visual inspection for color
and/or precipitate formation was recorded.
Data Analysis
Imipenem and cilastatin concentration and percent
recovery for each sample were calculated. Sample con-
centrations were calculated from a line generated by least
squares regression from the average of the six standard
curves according to the following equation: y = mx + b.
Drug recovery at time 0 was considered to be 100%; all
other values were determined from this point. The per-
cent recovery mean and standard deviation (unbiased)
were calculated for each sampling time. A change of
potency of more than 10% was considered to be signifi-
cant ; less than 90% recovery was considered to indicate
instability.&dquo;,&dquo;
RESULTS
Drug recovery from all samples analyzed is presented
in Table II. Imipenem (5 mg/ml) was stable (~90%
recovered) in TPN solutions 1 and 2 at 15 min. Imipenem
had significant (>10%) degradation in both TPN solu-
tions at 1 hr. In TPN solution 2, imipenem was com-
pletely degraded at 24 hr. Cilastatin was stable in TPN
solutions 1 and 2 at 30 min, and was generally more
stable than imipenem over time. Color observations and
pH measurements of all solutions are presented in Table
III. A gradual color change from colorless to dark orange
was observed over 24 hr in both TPN solutions. There
were no significant pH changes and no detectable precip-
itate during the study period.
DISCUSSION
Establishment of an intravenous product’s stability
with various intravenous solutions allows greater flexi-
bility and convenience for administration. Generally,
antibiotics and TPN solutions should be administered
through separate intravenous lines.&dquo; However, in certain
clinical situations, it would be advantageous to mix the
antibiotic with TPN solution or to administer them at a
Y-site with TPN solution.
This study demonstrated that imipenem-cilastatin so-
dium at a concentration of 5 mg/ml was stable in TPN
solutions 1 and 2 for 15 min (Table III). At 30 min
imipenem-cilastatin sodium remained stable in TPN so-
lution 2, but not in solution 1, and at 1 hr it was not
stable in either solution. Therefore, imipenem-cilastatin
sodium stability with the TPN solutions could not be
established after 15 to 30 min. Regardless of whether
stability is established at 15 or 30 min, direct admixture
of imipenem-cilastatin in a TPN bottle is not practical.
However, in clinical practice actual contact time between
imipenem-cilastatin sodium and TPN solution during
administration via a Y-site would be less than 30 min.
Gradual color change in both TPN solutions seemed
to be correlated with the degradation of imipenem and/
or cilastatin. Since both drug components were in solu-
tion together, the absolute relationship between degra-
dation of imipenem or cilastatin and the evolution of
color was indistinguishable. However, the color change
TABLE III
pH and color changes*
* Color was rated on a scale: 0 (colorless), 1 (pale yellow), 2 (yellow),
3 (dark yellow), 4 (orange), 5 (dark orange).
t See Table I for composition of solutions 1 and 2.
TABLE II
Stability of imipenem-cilastatin in two TPN solutions*
* See Table I for composition of solutions 1 and 2.
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appeared to be more closely related to the degradation of
imipenem, since the color intensified as imipenem con-
tinued to degrade while cilastatin remained relatively
intact. In addition, HPLC detection of degradation prod-
ucts appeared to be inversely proportional to decreased
imipenem detection and directly proportional to color
change.
CONCLUSION
Imipenem-cilastatin sodium is stable for 15 min in the
TPN solutions studied. However, until the stability of
the amino acids can be determined, imipenem-cilastatin
sodium should be administered according to the manu-
facturer’s recommendations through a separate intrave-
nous line or if necessary, at the TPN line Y-site while
the TPN infusion is temporarily interrupted.
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